Peptide Schedule
Substance P11 residuesRPKPQQFFGLMEach bubble = one amino acid. Size = residue mass. Color = chemical class.Substance P
Benefits
About Substance P
Substance P is an endogenous neuropeptide consisting of 11 amino acids (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) belonging to the tachykinin peptide family. Discovered in 1931, it is one of the most extensively studied neuropeptides in biomedical research. Substance P is widely distributed throughout the central and peripheral nervous systems and acts as a key neurotransmitter and neuromodulator. It signals primarily through the neurokinin-1 (NK1) receptor, mediating pain transmission, neurogenic inflammation, immune cell activation, and wound healing. Its dual role in both pro-inflammatory signaling and tissue repair makes it a critical molecule in understanding pain, inflammation, and immune responses.
Who Should Consider Substance P
- Researchers studying nociception and pain pathways
- Scientists investigating neurogenic inflammation mechanisms
- Clinicians researching wound healing and tissue regeneration
- Researchers exploring immune-neural crosstalk
- Investigators studying corneal wound repair
- Scientists developing NK1 receptor antagonist therapies (e.g., aprepitant)
How Substance P Works
Substance P binds with high affinity to the neurokinin-1 receptor (NK1R), a G-protein coupled receptor expressed on neurons, immune cells, endothelial cells, and keratinocytes. Upon binding, it activates phospholipase C via Gq/11 signaling, leading to intracellular calcium release and PKC activation. In nociceptive neurons, this amplifies pain signals transmitted from peripheral C-fibers to the spinal dorsal horn. In immune cells, NK1R activation promotes cytokine release (IL-1, IL-6, TNF-alpha), degranulation of mast cells, chemotaxis of neutrophils and macrophages, and T-cell proliferation. In wound healing, Substance P stimulates fibroblast proliferation, collagen synthesis, and angiogenesis through VEGF upregulation. It also mobilizes CD29+ stromal-like bone marrow cells to injury sites, contributing to tissue regeneration.
What to Expect
Rapid NK1 receptor activation. Immediate vasodilation and plasma extravasation at injection site. Mast cell degranulation and histamine release may occur. Effects are transient due to ~1-2 minute half-life.
Neurogenic inflammatory response peaks. Localized edema, erythema, and immune cell recruitment observed. Fibroblast and keratinocyte stimulation begins at the tissue level.
With repeated dosing, measurable increases in local immune cell infiltration and early wound healing markers. Bone marrow stem cell mobilization begins in animal models.
Accelerated wound closure and re-epithelialization observed in corneal and dermal wound models. Angiogenesis markers (VEGF) elevated. Collagen deposition increased at wound sites.
Maximal tissue repair effects in research models. Continued immune modulation. Evaluate inflammatory markers to ensure no chronic inflammation. Consider cycling off.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Daily |
| Moderate | 100mcg | Daily |
| Aggressive | 200mcg | Daily |
Note: Endogenous 11-amino-acid neuropeptide (RPKPQQFFGLM-NH2) of the tachykinin family. Primarily involved in pain signaling (nociception), neurogenic inflammation, and immune modulation via the NK1 receptor. Extremely short half-life limits direct therapeutic use — most clinical strategies target its receptor (NK1R) with antagonists rather than administering Substance P itself. Research use only.
How to Inject Substance P
Reconstitute lyophilized Substance P with bacteriostatic water. Administer subcutaneously for localized effects or intravenously for systemic research applications. Due to extremely rapid degradation (t1/2 ~1-2 minutes), continuous IV infusion is often used in clinical research settings. For subcutaneous use, inject near the target tissue area. Store reconstituted solution refrigerated and use within 7 days.
Cycling Protocol
Due to its pro-inflammatory nature, extended continuous use is not recommended. Short research cycles with equal off-periods are standard practice. Monitor inflammatory markers.
Pharmacokinetics
Source: Substance P is rapidly degraded by neutral endopeptidase (NEP/CD10) and angiotensin-converting enzyme (ACE) with a plasma half-life of approximately 1-2 minutes (PMID 24286369)
Loading the interactive decay curve.
Side Effects
Pro-inflammatory at higher doses — can induce vasodilation, edema, and neurogenic inflammation. May exacerbate pain perception and hyperalgesia. Can trigger mast cell degranulation and histamine release. Potential for bronchoconstriction in susceptible individuals. Nausea and flushing reported. Extremely short half-life necessitates frequent or continuous administration for any sustained effect.
Contraindications
- Active asthma or bronchoconstriction disorders — Substance P can induce bronchoconstriction via NK1R on airway smooth muscle
- Chronic inflammatory conditions (e.g., rheumatoid arthritis, IBD) — may exacerbate inflammation
- Pregnancy and breastfeeding — no safety data available
- Known hypersensitivity to tachykinin peptides
- Active malignancy — Substance P and NK1R signaling have been implicated in tumor growth and angiogenesis
- Neuropsychiatric conditions including major depression and anxiety disorders — Substance P is elevated in these conditions and exogenous administration may worsen symptoms
Drug Interactions
- NK1 receptor antagonists (aprepitant, fosaprepitant, netupitant) — directly block the target receptor, negating Substance P effects
- Opioid analgesics — additive effects on pain pathways; Substance P modulates opioid receptor sensitivity
- NSAIDs and corticosteroids — may partially counteract neurogenic inflammation induced by Substance P
- ACE inhibitors — ACE degrades Substance P; inhibition may potentiate and prolong Substance P effects, contributing to ACE-inhibitor cough
- Antihistamines — may blunt mast cell degranulation effects of Substance P
- Immunosuppressants — Substance P promotes immune activation, potentially counteracting immunosuppressive therapy
Storage & Stability
Molecular Profile
Related Peptides
References
- Substance P: a pioneer amongst neuropeptides (J Intern Med 2014)Review
- Substance P and the NK1 receptor: the new revolution in pain therapy (J Dent Res 2010)Review
- Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype (Am J Pathol 2017)PubMed 28315680
- Substance P stimulates human airway submucosal gland secretion mainly via a CFTR-dependent mechanism (J Clin Invest 1999)PubMed 10021467
- Substance P mobilizes mesenchymal stem cells and accelerates wound healing (Wound Repair Regen 2012)PubMed 22380690
- The role of substance P in inflammatory disease (J Cell Physiol 2004)Review